Compugen (CGEN) Competitors $1.39 -0.02 (-1.42%) Closing price 04:00 PM EasternExtended Trading$1.39 0.00 (0.00%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. RGNX, ZVRA, UPB, AMLX, ARVN, DNA, CGEM, ALT, SAGE, and SEPNShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include REGENXBIO (RGNX), Zevra Therapeutics (ZVRA), Upstream Bio (UPB), Amylyx Pharmaceuticals (AMLX), Arvinas (ARVN), Ginkgo Bioworks (DNA), Cullinan Therapeutics (CGEM), Altimmune (ALT), Sage Therapeutics (SAGE), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Compugen vs. REGENXBIO Zevra Therapeutics Upstream Bio Amylyx Pharmaceuticals Arvinas Ginkgo Bioworks Cullinan Therapeutics Altimmune Sage Therapeutics Septerna REGENXBIO (NASDAQ:RGNX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings. Do analysts recommend RGNX or CGEN? REGENXBIO currently has a consensus target price of $31.63, suggesting a potential upside of 224.13%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 190.91%. Given REGENXBIO's higher possible upside, research analysts plainly believe REGENXBIO is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RGNX or CGEN? REGENXBIO received 134 more outperform votes than Compugen when rated by MarketBeat users. Likewise, 65.44% of users gave REGENXBIO an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes44365.44% Underperform Votes23434.56% CompugenOutperform Votes30964.24% Underperform Votes17235.76% Which has more risk and volatility, RGNX or CGEN? REGENXBIO has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Which has stronger earnings & valuation, RGNX or CGEN? Compugen has lower revenue, but higher earnings than REGENXBIO. Compugen is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$156.72M3.12-$263.49M-$3.11-3.14Compugen$27.86M4.40-$18.75M-$0.16-8.59 Do insiders & institutionals believe in RGNX or CGEN? 88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to RGNX or CGEN? In the previous week, REGENXBIO had 17 more articles in the media than Compugen. MarketBeat recorded 29 mentions for REGENXBIO and 12 mentions for Compugen. REGENXBIO's average media sentiment score of 0.47 beat Compugen's score of -0.16 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is RGNX or CGEN more profitable? Compugen has a net margin of 2.67% compared to REGENXBIO's net margin of -283.19%. Compugen's return on equity of 2.62% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Compugen 2.67%2.62%1.36% SummaryREGENXBIO and Compugen tied by winning 9 of the 18 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.81M$2.94B$5.40B$8.53BDividend YieldN/A1.72%5.22%4.11%P/E Ratio68.2531.1826.7419.97Price / Sales4.40407.34394.93122.22Price / CashN/A168.6838.2534.62Price / Book1.883.346.874.59Net Income-$18.75M-$72.17M$3.23B$248.18M7 Day Performance4.96%6.07%5.01%2.15%1 Month Performance-1.08%9.51%12.82%16.14%1 Year Performance-26.08%-27.14%17.63%8.06% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.7391 of 5 stars$1.39-1.4%$4.00+187.8%-19.0%$124.04M$27.86M69.5070News CoverageEarnings ReportAnalyst RevisionRGNXREGENXBIO4.272 of 5 stars$9.79+10.1%$31.63+223.0%-37.0%$491.07M$156.72M-1.95370Analyst RevisionZVRAZevra Therapeutics3.2695 of 5 stars$8.91+2.9%$22.29+150.1%+83.6%$487.20M$23.61M-4.5220News CoverageAnalyst RevisionUPBUpstream Bio2.0917 of 5 stars$9.05+4.7%$56.50+524.3%N/A$486.84M$2.30M0.0038News CoverageAMLXAmylyx Pharmaceuticals3.4725 of 5 stars$5.36+10.7%$9.83+83.5%+200.0%$477.80M$-1,272,000.00-1.40200ARVNArvinas3.7292 of 5 stars$6.53+0.6%$20.92+220.3%-80.0%$476.63M$426.90M-2.36420DNAGinkgo Bioworks1.1224 of 5 stars$8.07+1.8%$5.77-28.5%N/A$468.33M$237.42M-0.62640Positive NewsCGEMCullinan Therapeutics2.3232 of 5 stars$7.71+2.8%$32.00+315.0%-67.1%$455.01MN/A-2.7130ALTAltimmune2.6299 of 5 stars$5.50-1.4%$20.20+267.3%-27.2%$446.09M$20,000.00-3.5550News CoverageAnalyst RevisionGap UpSAGESage Therapeutics3.955 of 5 stars$7.07+2.6%$8.81+24.6%-36.2%$442.73M$47.40M-1.07690Analyst DowngradeSEPNSepterna2.0614 of 5 stars$9.97+1.3%$27.00+170.8%N/A$438.04M$1.08M0.00N/AEarnings ReportAnalyst Revision Related Companies and Tools Related Companies REGENXBIO Alternatives Zevra Therapeutics Alternatives Upstream Bio Alternatives Amylyx Pharmaceuticals Alternatives Arvinas Alternatives Ginkgo Bioworks Alternatives Cullinan Therapeutics Alternatives Altimmune Alternatives Sage Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
